<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Diamond-Blackfan <z:hpo ids='HP_0001903'>anemia</z:hpo> (<z:chebi fb="28" ids="35299">DBA</z:chebi>) is a congenital <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> syndrome characterized by a specific deficiency in erythroid progenitors </plain></SENT>
<SENT sid="1" pm="."><plain>Forty percent of the patients are blood transfusion-dependent </plain></SENT>
<SENT sid="2" pm="."><plain>Recent reports show that the ribosomal protein S19 (RPS19) gene is mutated in 25% of <z:hpo ids='HP_0000001'>all</z:hpo> patients with <z:chebi fb="28" ids="35299">DBA</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>We constructed oncoretroviral vectors containing the RPS19 gene to develop gene therapy for RPS19-deficient <z:chebi fb="28" ids="35299">DBA</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>These vectors were used to introduce the RPS19 gene into CD34(+) bone marrow (BM) cells from 4 patients with <z:chebi fb="28" ids="35299">DBA</z:chebi> with RPS19 gene mutations </plain></SENT>
<SENT sid="5" pm="."><plain>Overexpression of the RPS19 transgene increased the number of erythroid colonies by almost 3-fold </plain></SENT>
<SENT sid="6" pm="."><plain>High expression levels of the RPS19 transgene improved erythroid colony-forming ability substantially whereas low expression levels had no effect </plain></SENT>
<SENT sid="7" pm="."><plain>Overexpression of RPS19 had no detrimental effect on granulocyte-macrophage colony formation </plain></SENT>
<SENT sid="8" pm="."><plain>Therefore, these findings suggest that gene therapy for RPS19-deficient patients with <z:chebi fb="28" ids="35299">DBA</z:chebi> using <z:mp ids='MP_0001799'>viral</z:mp> vectors that express the RPS19 gene is feasible </plain></SENT>
</text></document>